GWPH - 1 Picture You Need to See Before Writing Off GW Pharmaceuticals
We could probably all now agree that the biggest naysayers of GW Pharmaceuticals (NASDAQ: GWPH) and its CBD drug, Epidiolex, have been proved wrong. One GW skeptic said in 2018 that he'd "be shocked if annual Epidiolex sales ever reach $300 million." The drug topped that amount in its first full year on the market.
Even with the U.S. launch of Epidiolex surpassing expectations, some investors could still be concerned that GW Pharmaceuticals' share price already bakes in the growth potential for the drug. GW Pharmaceuticals CEO Justin Gover's presentation last week at the J.P. Morgan Healthcare Conference should give investors something to think about. There was one picture, in particular, in Gover's presentation that you need to see before writing off GW Pharmaceuticals.
Image source: GW Pharmaceuticals.